Journal article
MLL-TFE3: A novel and aggressive KMT2A fusion identified in infant leukemia
HJ Kosasih, NM Davidson, S Bjelosevic, E Morrish, MS Brennan, A Oshlack, RW Johnstone, G Brumatti, SL Khaw, PG Ekert
Blood Advances | ELSEVIER | Published : 2020
Abstract
A novel KMT2A-rearrangement, MLL-TFE3, was identified in an infant leukemia patient. MLL-TFE3 expression produces aggressive leukemia in a mouse model.
Grants
Awarded by Roche
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council (grant 1140626 [A.O., P.G.E., and N.M.D.] and grant 1081376 [G.B.]). P.G.E. and S.L.K. are investigators on Specialized Center of Research (SCOR) grant 7015-18 from the Lymphoma and Leukemia Society. S.L.K. and H.J.K. were supported by the Children's Cancer Foundation and the Department of Health and Human Services through the Victorian Cancer Agency (Project 134). G.B. was supported by Cancer Australia and Leukaemia Foundation Australia (priority grant PdCCRS 1162023) and the Victoria Cancer Agency (grant MCRF 15027). S.B. was supported by an Australian Government Research Training Program Scholarship and the Peter MacCallum Cancer Foundation. M.S.B. was supported by the Cancer Council Victoria. R.W.J. was supported by the Cancer Council Victoria, National Health and Medical Research Council of Australia, and The Kids' Cancer Project. This work was made possible through the Australian Cancer Research Foundation and Victorian State Government Operational Infrastructure Support and Australian Government (National Health and Medical Research Council Independent Research Institute Infrastructure Support Scheme [IRIISS] grant 9000433). The Peter MacCallum Foundation and Australian Cancer Research Foundation provided generous support for equipment and core facilities.